drugset
drugset / Trial / NCT02238782

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

NCT02238782 ↗

Phase 1 Completed 21 enrolled AstraZeneca
NaSingle-groupOpen-labelBasic science

Summary

To assess the absolute bioavailability of oral selumetinib in healthy male volunteers

Timeline

Start
2014-10
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Selumetinib Small molecule 75 mg Oral

Indications

No indication recorded.